Does Aetna Cover GLP-1 Medications in 2026?

Introduction

Aetna covers GLP-1 medications in 2026, but coverage depends on the specific plan, the indication (diabetes vs obesity vs cardiovascular vs OSA), and whether your employer carved out weight-loss drugs. There’s no single answer that applies to every Aetna member.

Aetna’s 2026 commercial formulary covers Ozempic® and Mounjaro® broadly for type 2 diabetes, with prior authorization. Wegovy® and Zepbound® coverage for obesity depends heavily on the plan: Aetna’s standard commercial PA criteria allow coverage with documentation, but a meaningful percentage of employer-sponsored plans have explicit carve-outs that exclude weight-loss drugs entirely. After the SELECT trial cardiovascular indication for Wegovy (FDA approved March 2024) and the SURMOUNT-OSA approval for Zepbound (December 2024), Aetna added separate coverage pathways for those medical indications, which often bypass the obesity carve-outs.

This is the breakdown by drug, plan type, and indication for 2026.

At TrimRx, we believe that understanding your options is the first step toward a more manageable health journey. You can take the free assessment quiz if you’re ready to see whether a personalized program is a fit for you.

Which Aetna Plans Cover Wegovy in 2026?

Aetna’s standard commercial plans cover Wegovy on Tier 3 of the formulary with prior authorization. The PA criteria require BMI 30 or higher (or 27 with a comorbidity such as type 2 diabetes, hypertension, dyslipidemia, OSA, or CVD), documentation of a 6-month structured weight management program, prescriber attestation that lifestyle change alone has failed, and age 18 or older.

Quick Answer: Aetna covers Ozempic and Mounjaro for type 2 diabetes with prior authorization on most commercial plans in 2026

A separate cardiovascular coverage pathway opened in 2024 after the SELECT trial (Lincoff et al. 2023, NEJM) showed 20 percent MACE reduction. Under the CV indication, patients with established cardiovascular disease and BMI 27+ qualify, and the 6-month lifestyle program is waived on most plans.

Employer-sponsored plans (self-funded ERISA plans) frequently carve out weight-loss drugs. About 35 to 40 percent of large employers exclude this category according to Mercer 2024 data. The exclusion is set by the employer, not Aetna.

What About Zepbound Coverage?

Aetna covers Zepbound on Tier 3 with prior authorization on standard commercial formularies for 2026. PA criteria match the Wegovy obesity pathway: BMI 30+, or 27+ with comorbidity, 6-month documented weight management program, prescriber attestation, age 18+.

The OSA pathway opened in December 2024 after FDA approval based on SURMOUNT-OSA (Malhotra et al. 2024, NEJM). Patients with moderate-to-severe OSA (AHI 15 or higher) and BMI 30+ qualify, and the 6-month lifestyle program requirement is waived on most plans under the OSA framing.

Step therapy is common. Aetna’s PA may require a documented trial of phentermine, Contrave, or Wegovy before Zepbound. Step requirements can be waived with documented intolerance or prior failure.

Does Aetna Cover Ozempic for Weight Loss?

No. Ozempic is FDA approved only for type 2 diabetes, not for weight loss. Aetna will not cover Ozempic if the prescription is written for weight loss. Off-label prescribing for weight loss without a diabetes diagnosis triggers an automatic denial.

For type 2 diabetes, Aetna covers Ozempic on most commercial plans with PA. Criteria typically include a documented diagnosis of T2DM (ICD-10 E11.x), prior trial or contraindication to metformin, and HbA1c documentation within the last 12 months.

The SUSTAIN program (multiple trials, NEJM and Lancet 2017 to 2019) supports Ozempic’s diabetes label. The SUSTAIN-6 trial showed cardiovascular benefit, which expanded the label in 2020.

Does Aetna Cover Mounjaro for Weight Loss?

No. Mounjaro is approved only for type 2 diabetes. Zepbound is the same molecule (tirzepatide) approved for obesity. If your prescription is written for weight loss, your prescriber should write Zepbound, not Mounjaro.

For type 2 diabetes, Aetna covers Mounjaro on Tier 3 of most commercial formularies with PA. The PA requires a confirmed T2DM diagnosis, recent HbA1c, and typically a prior metformin trial or documented contraindication.

The SURPASS program (multiple trials, NEJM and Lancet 2021 to 2022) supports the Mounjaro diabetes label. SURPASS-2 showed superiority to semaglutide on HbA1c reduction.

How Much Does Aetna Pay vs the Member?

Tier 3 medications on Aetna commercial plans typically have copays between $50 and $100 per month after deductible, or coinsurance of 30 to 50 percent. The exact share depends on plan design.

Without insurance, list prices in 2026 are roughly: Wegovy $1,349 per month, Zepbound $1,086 per month (auto-injector) or $349 to $549 (vials through LillyDirect), Ozempic $998 per month, Mounjaro $1,069 per month.

With manufacturer savings cards, commercially insured patients can often pay $0 to $25 per month if the PA is approved. Without insurance, the Novo Nordisk NovoCare direct program offers Wegovy at $499 and LillyDirect offers Zepbound vials at $349 to $549.

Key Takeaway: The SELECT trial cardiovascular indication for Wegovy and the SURMOUNT-OSA indication for Zepbound create separate coverage pathways

What If Aetna Denies Coverage?

You have 180 days from the denial date to file a level-1 internal appeal. About 41 percent of commercial denials are overturned with new documentation (CMS 2023). Submit a written appeal, a Letter of Medical Necessity from the prescriber, chart notes, BMI history, and documentation of the 6-month weight management program.

If the level-1 denial is upheld, file a level-2 internal appeal within 60 days and an external review through your state insurance commissioner within 4 months. External review is free, independent, and binding on Aetna.

For Wegovy denials, lead with the SELECT trial cardiovascular pathway if you have any CVD history. For Zepbound denials, lead with SURMOUNT-OSA if you have a recent sleep study showing AHI 15+.

Does Aetna Medicare Cover GLP-1s?

Aetna Medicare Part D in 2026 covers Ozempic and Mounjaro for type 2 diabetes with PA. Wegovy is covered for the cardiovascular indication (CVD plus overweight or obesity) following the CMS coverage update in March 2024, not for weight loss alone. Zepbound is covered under Medicare for the OSA indication starting in 2025.

Medicare statute (Section 1860D-2(e)(2)(A)) prohibits Part D coverage of “drugs for weight loss.” The 2024 CMS guidance carved out exceptions for FDA-approved medical indications outside of weight loss itself.

Coverage for any of these still requires PA with documentation matching the specific indication.

Are There Compounded GLP-1 Options If Coverage Is Denied?

Yes. Compounded semaglutide and compounded tirzepatide remain legal when prescribed by a licensed provider for an individual patient based on clinical need. The active ingredients match Wegovy and Zepbound respectively.

Telehealth platforms like TrimRx offer a free assessment quiz that determines eligibility for a personalized treatment plan. Compounded options typically run $199 to $499 per month depending on dose, dramatically below brand-name cash prices.

Compounded medications come from licensed 503A pharmacies and are prescribed individually after a clinical evaluation. The pathway is regulated by state boards of pharmacy and the prescribing provider’s medical license.

What’s the Difference Between Brand-name and Compounded?

Brand-name medications (Wegovy, Zepbound) are FDA approved and manufactured by Novo Nordisk and Eli Lilly. They go through FDA’s drug approval process and carry the exact dosing studied in trials.

Compounded medications use the same active pharmaceutical ingredient but are made by a licensed 503A pharmacy for a specific patient based on a prescription. Compounding is regulated under state pharmacy law and FDA section 503A. The pricing is lower because there’s no patent royalty and no large-scale manufacturing infrastructure.

Both are prescription medications and both require clinical evaluation before use.

Bottom line: Employer-sponsored plans can carve out weight-loss drugs, and this is not appealable through Aetna

FAQ

Does Aetna Cover Semaglutide for Prediabetes?

No. Semaglutide is not FDA approved for prediabetes. Aetna will not cover Ozempic, Wegovy, or any branded semaglutide for prediabetes. For prediabetes management, Aetna covers lifestyle programs and metformin under most commercial plans.

Will Aetna Require STEP Therapy with Phentermine Before Wegovy?

Often yes, depending on the plan. Step therapy can be waived with documented intolerance to phentermine, prior failure to lose weight on phentermine, or contraindication (cardiovascular disease, uncontrolled hypertension, seizure history). Submit the documentation as part of the PA or first appeal.

What If My Employer Plan Excludes Weight-loss Drugs?

The exclusion is set by the employer, not Aetna, and cannot be appealed through Aetna. Three options: check whether the exclusion applies to all indications or only obesity, request a formulary exception based on the CV or OSA indication if applicable, or look at compounded GLP-1 options through telehealth.

How Long Does Aetna Prior Authorization Take?

Standard PA: 72 hours. Expedited PA (when delay would jeopardize health): 24 hours. If Aetna doesn’t respond within those windows, the PA is automatically approved under federal regulations.

Can My Doctor Request a Peer-to-peer Review?

Yes. After a denial, your prescriber can call Aetna’s medical director directly for a peer-to-peer review. The call usually lasts 10 to 20 minutes and resolves a significant share of denials in real time. Your prescriber’s office initiates the call from the number on the denial letter.

Does Aetna Cover the Cost of a Sleep Study to Qualify for Zepbound Under OSA?

Yes. Sleep studies are covered under standard medical benefits, separate from pharmacy benefits, with PA typically required. The study results (AHI 15 or higher) then support the Zepbound OSA pathway.

How Often Do I Need to Renew the PA?

Aetna typically approves Wegovy and Zepbound PAs for 12 months at a time. Renewal requires documentation of clinical response, usually defined as at least 5 percent weight loss at 6 months or other clinical improvement matching the indication.

Disclaimer: This content is for informational purposes only and does not constitute medical advice. It is not intended to diagnose, treat, cure, or prevent any disease or condition. Individual results may vary. Always consult a qualified healthcare professional before starting any weight loss program or medication.

Related Articles

• Does Humana Cover GLP-1 Medications in 2026?
• Does Medicare Cover GLP-1 Medications in 2026?
• Does Cigna Cover GLP-1 Medications in 2026?
• Does BCBS Blue Cross Blue Shield Cover GLP-1 Medications in 2026?